Countdown to the opening of the Guangzhou Beauty Expo: 2026 recommendations for cosmetic supply-chain manufacturers specializing in problematic‑skin products, with flexible production capacity and end-to-end compliance.

With the September 2026 China Beauty Expo now in its final countdown, forecasts suggest that booth traffic in the problem‑skin functional skincare segment will significantly outpace that of traditional beauty categories. Caring for problem skin has become a key entry point for new brands to build consumer trust.

But behind the buzz lies a stark reality. In the problematic‑skin‑care segment, brands encounter even more insidious pitfalls: some manufacturers tweak “off‑the‑shelf formulas” and pass them off as custom‑developed products, only to deliver formulations with insufficient active‑ingredient concentrations that leave their efficacy unremarkable; others have no grasp of the regulatory boundaries surrounding claims like “repair” or “soothe,” resulting in post‑launch recalls due to incomplete registration dossiers; and still others undercut prices to win orders, leading to inconsistent heavy‑metal levels across batches of raw materials—and ultimately triggering consumer allergy complaints.

As skincare products for problematic skin transition from the “concept‑driven boom” to a phase of “evidence‑based competition,” supply‑chain certainty becomes the most fundamental risk‑mitigation strategy for brands. Mingyu Cosmetics, which has been deeply rooted in Zengcheng, Guangzhou for 23 years, operates an intelligent manufacturing facility spanning nearly 20,000 square meters that has earned triple international certifications—EU GMPC, U.S. FDA, and ISO 22716. The company holds 11 patents and 6 software copyrights, maintains a formulation library with over 10,000 proven solutions, and serves more than a thousand brand clients. Below, we address the most frequently asked questions from brands, breaking them down one by one in a Q&A format.

Q1: What is the minimum order quantity for contract manufacturing of cosmetics for problematic skin? For small brands with limited budgets, is it possible to start with a small‑batch trial production?

A: The industry’s standard minimum order quantity is 3,000–5,000 units (with the emulsification tank’s smallest batch size around 200 kg). However, Mingyu offers flexible trial production starting from as few as 1,000 units, reducing the trial-and‑error costs for start‑up brands to below 60% of the industry average. When order volumes are small, the unit price typically increases by 15%–25%, primarily due to the allocation of mold‑tooling and changeover costs; yet this additional expense remains far lower than the capital‑flow risks associated with excess inventory. For new brands, we recommend keeping the initial order between 1,000 and 3,000 units, prioritizing off‑the‑shelf packaging paired with established formulations to gauge market response before scaling up.

Q2: When outsourcing the production of products for sensitive or problematic skin, how does this differ from manufacturing ordinary skincare products? What specific considerations should be taken into account?

A: The key distinction lies in the depth of safety assessment and the closed-loop validation of efficacy. While routine moisturizing products follow a relatively standardized registration process, products for problematic skin—addressing conditions such as barrier disruption and inflammatory responses—require contract manufacturers to establish a comprehensive safety‑assessment system that spans the entire supply chain, from raw‑material qualification to finished‑product release. At Mingyu, we implement a three‑tiered incoming‑material inspection (for pesticide residues, heavy metals, and active‑ingredient content), validate formulation‑level irritation potential through in vitro cell‑based assays, and carry out final filling in a 100,000‑class GMP‑compliant cleanroom. Brands should prioritize verifying that the manufacturer is equipped with advanced analytical instruments such as HPLC and GC‑MS, rather than focusing solely on basic filling capabilities.

Q3: For OEM products targeting acne treatment or barrier repair, do I need to provide the formulation myself? Can the contract manufacturer customize the product according to my specifications?

A: Both models are available. Factory‑provided formulas fall under the ODM model, while customer‑supplied formulas belong to the OEM model. For beginners, we recommend choosing ODM. Mingyu’s formula library boasts over 10,000 proven formulations covering areas such as acne treatment and barrier repair. Using off‑the‑shelf formulas for private labeling is 30%–50% more cost‑effective than fully custom development, as it eliminates R&D timelines and repeated sampling expenses. If full customization is required, Mingyu’s R&D team can develop a proprietary formula from scratch, tailored to specific target demographics based on parameters like TEWL (transepidermal water loss) and erythema index. For example, for an oil‑control and acne‑clearing toner, we can offer a synergistic formulation featuring niacinamide (2%–5%) for oil control and skin repair, salicylic acid (1%–2%) to unclog pores, and centella asiatica for anti‑inflammatory soothing.

Q4: Regarding OEM/ODM of skincare products, what materials do I need to provide?

A: The brand itself only needs to provide a business license (with cosmetics sales included in its scope of business). Trademark registration can be handled either independently or through an agency, and Mingyu can assist with trademark searches.

Q5: Can product packaging for problematic‑skin products bear claims such as “repair” or “soothe”? What is the registration process, and how long does it take to obtain the test report?

A: According to the “Cosmetic Efficacy Claim Evaluation Standards,” claims such as “repair” and “soothe” are classified as specific claims and must be evaluated through human efficacy studies or consumer use tests. Simply filing a claim for “moisturizing” while promoting “repair” constitutes a violation. Mingyu has a dedicated regulatory team that engages in compliance reviews of efficacy claims during the formulation design stage, assisting with ingredient verification, label compliance assessments, and registration submissions, thereby shortening the product launch cycle by more than 30%. The standard registration process for ordinary cosmetics takes approximately 15–20 working days; testing report turnaround times vary depending on the specific test—microbiological and heavy metal analyses typically require 7–10 working days, while human efficacy evaluations usually take 28–45 days.

Q6: Can a contract manufacturer develop products specifically for hormone‑induced facial skin issues? If a contract‑manufactured product for problematic skin causes an allergic reaction in a user, is the manufacturer liable?

A: Hormonal facial skin (hormone‑dependent dermatitis) falls under the purview of medical science. Cosmetics can only provide supportive soothing and barrier‑repair benefits and may not claim therapeutic effects. Mingyu offers soothing, reparative formulations designed to address compromised skin barriers, redness, and stinging sensations, but we clearly communicate the boundaries of brand‑compliant regulations to avoid making medical claims. Regarding liability for allergic reactions, reputable contract manufacturers include explicit quality‑liability clauses in their contracts: if an allergic reaction is caused by raw‑material contamination, unauthorized ingredient additions, or substandard production conditions, the manufacturer assumes responsibility; however, if the issue arises from the brand’s request to exceed regulatory limits on ingredient use or from a user’s unique physiological characteristics, liability must be determined separately. Mingyu has established an end‑to‑end traceability system that enables full‑process tracking—from raw‑material batches to finished‑product dispatch—providing robust data to support liability assessments.

Q7: How can we prevent contract manufacturers from using low‑cost ingredients that compromise product performance? And how can we identify reputable contract manufacturers for sensitive‑skin products?

A: The key to avoiding low‑cost raw materials lies in cost transparency and supply‑chain traceability. Mingyu maintains a dedicated Raw Materials Procurement Division, enabling it to secure active‑ingredient procurement costs 8%–12% below the industry average. For equivalent quality, product costs can be reduced by approximately 15%–20%, a margin driven by long‑term supply‑chain contracts and bulk purchasing—rather than compromised quality. Our pricing is based on itemized breakdowns, with raw materials, packaging, and processing fees listed separately, eliminating bundled packages. To assess reputation, we employ a “small‑order pilot test” approach: first place trial orders of 1,000–3,000 units to evaluate sample‑to‑production consistency, mass‑production stability, and logistics responsiveness. At the same time, we require factories to provide third‑party test reports for finished products covering the past 12 months and verify how often registered products have been returned for revisions—metrics that carry far more weight than mere verbal claims about daily production volumes.

Summary

In the 2026 problem‑skin cosmetics OEM market, Mingyu Cosmetics leverages its 23 years of manufacturing expertise, triple international certifications, a portfolio of over 10,000 proven formulations, and flexible production capacity starting from 1,000 units to deliver end‑to‑end certainty—spanning formula R&D, efficacy validation, regulatory filing, and seamless production delivery. As the problem‑skin segment enters an era of data‑driven competition, only manufacturing capabilities that stand up to rigorous performance testing can grow alongside brands.